KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Current Liabilities (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Total Current Liabilities for 18 consecutive years, with $716.6 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 186.3% year-over-year to $716.6 million; the TTM value through Mar 2026 reached $716.6 million, up 186.3%, while the annual FY2025 figure was $781.6 million, 152.67% up from the prior year.
  • Total Current Liabilities hit $716.6 million in Q1 2026 for Ionis Pharmaceuticals, down from $781.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $903.5 million in Q3 2025 and bottomed at $228.4 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $428.7 million, with a median of $309.3 million recorded in 2024.
  • Year-over-year, Total Current Liabilities plummeted 30.97% in 2024 and then surged 196.64% in 2025.
  • Ionis Pharmaceuticals' Total Current Liabilities stood at $311.6 million in 2022, then skyrocketed by 43.82% to $448.1 million in 2023, then tumbled by 30.97% to $309.3 million in 2024, then soared by 152.67% to $781.6 million in 2025, then fell by 8.31% to $716.6 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $716.6 million, $781.6 million, and $903.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.